177 related articles for article (PubMed ID: 35705315)
21. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
22. Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors.
Su X; Lu X; Bazai SK; Dainese L; Verschuur A; Dumont B; Mouawad R; Xu L; Cheng W; Yan F; Irtan S; Lindner V; Paillard C; Le Bouc Y; Coulomb A; Malouf GG
Nat Commun; 2023 Nov; 14(1):7884. PubMed ID: 38036539
[TBL] [Abstract][Full Text] [Related]
23. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract][Full Text] [Related]
24. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
Song J; Yang R; Wei R; Du Y; He P; Liu X
Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
[TBL] [Abstract][Full Text] [Related]
25. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the treatment-naive immune microenvironment in melanoma with
Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
[TBL] [Abstract][Full Text] [Related]
28. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
29. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
30. Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.
Korabiowska M; König F; Verheggen R; Schlott T; Cordon-Cardo C; Romeike B; Brinck U
Anticancer Res; 2004; 24(2B):981-6. PubMed ID: 15161053
[TBL] [Abstract][Full Text] [Related]
31. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma.
Fischer S; Hamed M; Emmert S; Wolkenhauer O; Fuellen G; Thiem A
Front Oncol; 2022; 12():810058. PubMed ID: 35174087
[TBL] [Abstract][Full Text] [Related]
33. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
Lei S; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
[TBL] [Abstract][Full Text] [Related]
34. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
35. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
36. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
37. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
38. Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response.
Ahmed KM; Veeramachaneni R; Deng D; Putluri N; Putluri V; Cardenas MF; Wheeler DA; Decker WK; Frederick AI; Kazi S; Sikora AG; Sandulache VC; Frederick MJ
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002187
[TBL] [Abstract][Full Text] [Related]
39. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
[TBL] [Abstract][Full Text] [Related]
40. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
Front Immunol; 2021; 12():758288. PubMed ID: 34804045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]